Premium
Proton MRS in mild cognitive impairment
Author(s) -
Kantarci Kejal
Publication year - 2013
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.23800
Subject(s) - dementia , magnetic resonance imaging , medicine , biomarker , disease , cognitive impairment , pathology , prodromal stage , proton magnetic resonance , neuroimaging , lewy body , pathophysiology , alzheimer's disease , psychology , radiology , psychiatry , nuclear magnetic resonance , biology , biochemistry , physics
Mild cognitive impairment (MCI) is a clinical syndrome operationalized for early diagnosis and treatment of Alzheimer's disease (AD). Many individuals with MCI are at the prodromal stage of AD or other dementia. Various quantitative magnetic resonance imaging (MRI) techniques that measure the anatomic, biochemical, microstructural, functional, and blood‐flow changes are being evaluated as possible surrogate measures for early diagnosis and disease progression in MCI. The pathology underlying MCI is heterogeneous, dominated by AD, cerebrovascular disease, Lewy body disease, or a mixture of these pathologies in autopsy cohorts. Proton magnetic resonance spectroscopy ( 1 H MRS) metabolite markers may help identify and track etiologies that typically underlie MCI in the elderly. The role of proton MRS will be critical for pathophysiological processes for which a reliable biomarker does not exist such as neuronal dysfunction, glial and microglial activation in MCI. J. Magn. Reson. Imaging 2013;37:770–777. © 2012 Wiley Periodicals, Inc.